The successful treatment of Graves’ ophthalmopathy (GO) remains a challenge, while the efficacy of rituximab (RTX) is at present controversial. The aim of this meta-analysis was to investigate the potential impact of intravenous RTX therapy in patients with GO.
We performed a search in the PubMed, Embase, and Web of Science databases for relevant studies published before July 2020. The primary outcome was the change of clinical activity score (CAS), and secondary outcomes were the change of proptosis and TSH receptor antibodies (TRAb). A meta-analysis was conducted to calculate the standard mean difference (SMD) for these outcomes by using fixed- or random-effect models.
Analysis of outcomes in 152 patients collected from 12 published articles was conducted. Compared to baseline value, CAS was significantly decreased at 1, 6, 12, and >12 months after RTX treatment. For proptosis, the results revealed no significant decrease at 1–3, 6, and ≥12 months. Moreover, the pooled analysis employed in this meta-analysis showed no significant difference of TRAb at 1 month, but significant declines were observed at 6 and ≥12 months.
Our results strongly suggest that intravenous RTX treatment has an acute and long-lasting beneficial effect on decreasing both CAS and TRAb. The study also indicates that the effect of RTX on proptosis is limited. There is evidently a need to investigate the mechanism behind RTX ineffectiveness on proptosis and explore other therapeutic regimens for the reduction of proptosis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362(8):726–738. https://doi.org/10.1056/NEJMra0905750 [published Online First: 2010/02/26]
Smith TJ (2010) Pathogenesis of Graves’ orbitopathy: a 2010 update. J Endocrinol Investig 33(6):414–421. https://doi.org/10.1007/bf03346614 [published Online First: 2010/07/16]
Bartalena L, Tanda ML (2009) Clinical practice. Graves’ ophthalmopathy. N Engl J Med 360(10):994–1001. https://doi.org/10.1056/NEJMcp0806317 [published Online First: 2009/03/07]
Shen WC, Lee CH, Loh EW et al (2018) Efficacy and safety of rituximab for the treatment of Graves’ orbitopathy: a meta-analysis of randomized controlled trials. Pharmacotherapy 38(5):503–510. https://doi.org/10.1002/phar.2111 [published Online First: 2018/03/31]
Prummel MF, Bakker A, Wiersinga WM et al (2003) Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol 148(5):491–495. https://doi.org/10.1530/eje.0.1480491 [published Online First: 2003/05/02]
Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320–332. https://doi.org/10.1210/jc.2010-1962 [published Online First: 2011/01/18]
Kahaly GJ, Pitz S, Hommel G et al (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90(9):5234–5240. https://doi.org/10.1210/jc.2005-0148 [published Online First: 2005/07/07]
Bartalena L, Krassas GE, Wiersinga W et al (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab 97(12):4454–4463. https://doi.org/10.1210/jc.2012-2389 [published Online First: 2012/10/06]
Khong JJ, McNab A (2020) Medical treatment in thyroid eye disease in 2020. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2020-316051 [published Online First: 2020/05/25]
Shen S, Chan A, Sfikakis PP et al (2013) B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Surv Ophthalmol 58(3):252–265. https://doi.org/10.1016/j.survophthal.2012.10.006 [published Online First: 2012/12/21]
Salvi M, Vannucchi G, Currò N et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100(2):422–431. https://doi.org/10.1210/jc.2014-3014 [published Online First: 2014/12/17]
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535 [published Online First: 2009/07/23]
Salvi M, Vannucchi G, Campi I et al (2007) Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156(1):33–40. https://doi.org/10.1530/eje.1.02325 [published Online First: 2007/01/16]
Khanna D, Chong KK, Afifiyan NF et al (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117(1):133–39.e2. https://doi.org/10.1016/j.ophtha.2009.05.029 [published Online First: 2009/10/13]
Silkiss RZ, Reier A, Coleman M et al (2010) Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 26(5):310–314. https://doi.org/10.1097/IOP.0b013e3181c4dfde [published Online First: 2010/06/22]
Mitchell AL, Gan EH, Morris M et al (2013) The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves’ orbitopathy. Clin Endocrinol 79(3):437–442. https://doi.org/10.1111/cen.12141 [published Online First: 2013/01/17]
Erdei A, Paragh G, Kovacs P et al (2014) Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves’ orbitopathy: a five-year follow-up study. Autoimmunity 47(8):548–555. https://doi.org/10.3109/08916934.2014.939266 [published Online First: 2014/07/22]
Stan MN, Garrity JA, Carranza Leon BG et al (2015) Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 100(2):432–441. https://doi.org/10.1210/jc.2014-2572 [published Online First: 2014/10/25]
Karasek D, Cibickova L, Karhanova M et al (2017) Clinical and immunological changes in patients with active moderate-to-severe Graves’ orbitopathy treated with very low-dose rituximab. Endokrynol Pol 68(5):498–504. https://doi.org/10.5603/EP.a2017.0040 [published Online First: 2017/07/01]
Insull EA, Sipkova Z, David J et al (2019) Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment. Clin Endocrinol 91(1):179–186. https://doi.org/10.1111/cen.13970 [published Online First: 2019/03/14]
Du Pasquier-Fediaevsky L, Andrei S, Berche M et al (2019) Low-dose rituximab for active moderate to severe Graves’ orbitopathy resistant to conventional treatment. Ocul Immunol Inflamm 27(5):844–850. https://doi.org/10.1080/09273948.2018.1453078 [published Online First: 2018/04/14]
Eid L, Coste-Verdier V, Longueville E et al (2020) The effects of rituximab on Graves’orbitopathy: a retrospective study of 14 patients. Eur J Ophthalmol 30(5):1008–1013. https://doi.org/10.1177/1120672119845224 [published Online First: 2019/04/27]
Deltour JB, d’Assigny Flamen M, Ladsous M et al (2020) Efficacy of rituximab in patients with Graves’ orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol 258(9):2013–2021. https://doi.org/10.1007/s00417-020-04651-6 [published Online First: 2020/05/15]
Ponto KA, Merkesdal S, Hommel G et al (2013) Public health relevance of Graves’ orbitopathy. J Clin Endocrinol Metab 98(1):145–152. https://doi.org/10.1210/jc.2012-3119 [published Online First: 2012/11/28]
Wang C, Ning Q, Jin K et al (2018) Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis. BMC Ophthalmol 18(1):46. https://doi.org/10.1186/s12886-018-0679-4 [published Online First: 2018/02/18]
Salvi M, Vannucchi G, Beck-Peccoz P (2013) Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab 98(11):4291–4299. https://doi.org/10.1210/jc.2013-1804 [published Online First: 2013/09/07]
Stan MN, Salvi M (2017) Management of endocrine disease: rituximab therapy for Graves’ orbitopathy - lessons from randomized control trials. Eur J Endocrinol 176(2):R101–Rr09. https://doi.org/10.1530/eje-16-0552 [published Online First: 2016/10/21]
Taylor PN, Zhang L, Lee RWJ et al (2020) New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 16(2):104–116. https://doi.org/10.1038/s41574-019-0305-4 [published Online First: 2020/01/01]
Lacheta D, Miskiewicz P, Gluszko A et al (2019) Immunological aspects of Graves’ ophthalmopathy. Biomed Res Int 2019:7453260. https://doi.org/10.1155/2019/7453260 [published Online First: 2019/11/30]
Li J, Xiao Z, Hu X et al (2017) The efficacy of rituximab combined with 131i for ophthalmic outcomes of Graves’ ophthalmopathy patients. Pharmacology 99(3-4):144–152. https://doi.org/10.1159/000453618 [published Online First: 2017/01/04]
Savino G, Balia L, Colucci D et al (2013) Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series. Minerva endocrinol 38(2):173–179 [published Online First: 2013/06/05]
Wall JR, Lahooti H (2011) Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol 62(Suppl 1):1–7 [published Online First: 2012/01/10]
Mishra S, Maurya VK, Kumar S et al (2020) Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives. Curr Eye Res:1–17. https://doi.org/10.1080/02713683.2020.1776331 [published Online First: 2020/06/23]
Diana T, Brown RS, Bossowski A et al (2014) Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves’ disease-a multicenter study. J Clin Endocrinol Metab 99(5):1648–1655. https://doi.org/10.1210/jc.2013-4026 [published Online First: 2014/02/13]
El Fassi D, Nielsen CH, Bonnema SJ et al (2007) B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J Clin Endocrinol Metab 92(5):1769–1772. https://doi.org/10.1210/jc.2006-2388 [published Online First: 2007/02/08]
Vannucchi G, Campi I, Bonomi M et al (2010) Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol 161(3):436–443. https://doi.org/10.1111/j.1365-2249.2010.04191.x [published Online First: 2010/06/10]
Vos K, Thurlings RM, Wijbrandts CA et al (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56(3):772–778. https://doi.org/10.1002/art.22400 [published Online First: 2007/03/01]
Ethics approval and consent to participate
All analyses were based on previously published studies; thus, no ethical approval was required.
All analyses were based on previous published studies; thus, no informed consent was required.
Conflict of interest
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Chen, J., Chen, G. & Sun, H. Intravenous rituximab therapy for active Graves’ ophthalmopathy: a meta-analysis. Hormones (2021). https://doi.org/10.1007/s42000-021-00282-6
- Graves’ ophthalmopathy